1stOncology™: Cancer Intelligence Service – Page 11918 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Regulus Therapeutics to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference

On September 11, 2020 Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), reported that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 11:00 AM EDT (Press release, Regulus, SEP 11, 2020, https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-hc-wainwright-22nd-annual-virtual-global-investment-conference-301128135.html [SID1234565034]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available through the investor relations section of the Company’s website at www.regulusrx.com.

Natera’s Signatera™ MRD Test Receives a Final Coverage Decision from Noridian in Colorectal Cancer

On September 11, 2020 Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, reported that Noridian, the Medicare Administrative Contractor (MAC) for Northern California, has finalized a final local coverage article (LCA) to provide Medicare benefits for serial use of the Signatera molecular residual disease (MRD) test in patients with a history of colorectal cancer (Press release, Natera, SEP 11, 2020, View Source [SID1234565033]).

The Noridian article is in line with the positive coverage determination issued by the CMS Molecular Diagnostics (MOLDX) program last week via Palmetto GBA and shares the same effective date of October 18th, 2020.

AIkido Pharma Inc. Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)

On September 11, 2020 AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") reported it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, AIkido Pharma, SEP 11, 2020, https://www.prnewswire.com/news-releases/aikido-pharma-inc-announces-participation-at-the-hc-wainwright-22nd-annual-global-investment-conference-on-september-14-16-2020-virtual-conference-301128171.html [SID1234565032]). The conference is being held on September 14-16, 2020 virtually.

Darrell Dotson, Vice President and General Counsel, of AIkido Pharma Inc. will provide an overview of the Company’s business during the live presentation.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference.

Event: H.C. Wainwright 22nd Annual Global Investment Conference (Virtual Conference)
Date: Tuesday, September 15, 2020
Time: 3:00 p.m. (Eastern Time)
Location: Virtual Conference
Webcast: View Source

The presentation will be webcast live. To access the webcast, please visit www.hcwevents.com . The webcast replay will remain available for 90 days following the live presentation.

About H.C. Wainwright

H.C. Wainwright is a full–service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

Lilly to Participate in Morgan Stanley Global Healthcare Conference

On September 11, 2020 Eli Lilly and Company (NYSE: LLY) reported that it will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2020. Joshua Smiley, senior vice president and Lilly’s chief financial officer, will participate in a virtual fireside chat at 3:30 p.m., Eastern Time (Press release, Eli Lilly, SEP 11, 2020, View Source [SID1234565031]).

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

CEL-SCI Corporation to Present at H.C. Wainwright 22nd Annual Global Investment Conference

On September 11, 2020 CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, reported that it will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, Cel-Sci, SEP 11, 2020, View Source [SID1234565030]). The virtual conference will be held on September 14-16, 2020. Geert Kersten, Chief Executive Officer of CEL-SCI, will present on Monday, September 14 at 1:30 p.m. ET.

For those who wish to listen to the live webcast, please use the following link View Source The webcast will be archived on CEL-SCI’s investor relations website, View Source for 90 days following the live presentation.